Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00779935
Recruitment Status : Completed
First Posted : October 24, 2008
Last Update Posted : May 11, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This is a Phase 4, multi-center, open-label, one-arm, pilot study in patients with active ankylosing spondylitis refractory to conventional treatment. Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54. The number of patients showing ASAS-20 clinical response at Week 14 will be evaluated.

Condition or disease Intervention/treatment Phase
Spondylitis, Ankylosing Biological: Remicade Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study
Actual Study Start Date : October 1, 2004
Actual Primary Completion Date : October 1, 2005
Actual Study Completion Date : February 1, 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Remicade
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Biological: Remicade
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Other Names:
  • Infliximab
  • SCH 215596

Primary Outcome Measures :
  1. To investigate whether baseline serum VEGF concentration predicts ASAS-20 clinical response to infliximab at Week 14. [ Time Frame: Week 14 ]

Secondary Outcome Measures :
  1. To detect clinical response rates at Weeks 2, 6, 14, 30, 54, and at Follow-up Visit 2, which is 6 months after completion of study treatment. [ Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards ]
  2. To measure the duration of response [ Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards ]
  3. To detect the percent of patients reaching partial response [ Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards ]
  4. To measure the duration of partial response [ Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis proven by appropriate diagnostic methods (according to New York criteria).
  • Refractory disease defined by failure of at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) during a 3-month period and failure of sulfasalazine in subjects with associated peripheral arthritis.
  • Active disease defined by:

    • sustained BASDAI of at least 40 on a 0-100 scale and
    • expert opinion based on clinical features.
  • Age between 18 and 70 years.
  • Subjects using NSAIDs and/or sulfasalazine must have been on a stable dose for at least 4 weeks prior to study initiation, and may continue medication during the treatment period, but the dose must not be increased above the baseline.
  • Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
  • Men and women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation).
  • Subjects must understand and be able to adhere to the dosing and visit schedules.

Exclusion Criteria:

  • Subject with moderate or severe heart failure (NYHA class III/IV).
  • Remicade must not be given to subjects with a history of hypersensitivity to infliximab, to other murine proteins, or to any of the excipients.
  • Subjects with pre-existing or recent onset of central nervous system demyelinating disorders.
  • Age <18 or >70 years.
  • Pregnant women, nursing mothers.
  • Subjects who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
  • Subjects who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from infliximab therapy.
  • Prior administration of infliximab or any other therapeutic agent targeted at reducing TNF (eg, Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody).
  • Current treatment with systemic corticosteroid.
  • Treatment with any investigational drug within the previous 3 months.
  • History of known allergies to murine proteins.
  • Subjects having active or inactive tuberculosis (TB). All subjects must be evaluated for both active and inactive ('latent') TB. This evaluation should include a detailed medical history with personal history of TB or possible previous contact with TB and previous and/or current immunosuppressive therapy. Appropriate screening tests (ie, tuberculin skin test and chest x-ray) should be performed in all subjects.
  • Serious infection, such as sepsis, abscesses, hepatitis, pneumonia, pyelonephritis in the previous 3 months. Less serious infections in the previous 3 months, such as acute respiratory tract infection (colds) or uncomplicated urinary tract infection need not be considered exclusions at the discretion of the treating physician.
  • History of opportunistic infections such as herpes zoster within 2 months of study initiation. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium, etc.
  • Documented HIV infection.
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
  • Any currently known malignancy or pre-malignant lesions or any history of malignancy within the past 5 years (except non-melanoma skin cancer and surgically cured cervical cancer).
  • Subjects with alcoholism, alcoholic liver disease, or other chronic liver disease.

Study Data/Documents: CSR Synopsis  This link exits the site

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00779935     History of Changes
Other Study ID Numbers: P04041
First Posted: October 24, 2008    Key Record Dates
Last Update Posted: May 11, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Endothelial Growth Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents
Growth Substances
Physiological Effects of Drugs